Results 201 to 210 of about 4,464,251 (309)

Comparable survival outcome with anti-EGFR therapy in any treatment line in left-sided metastatic colorectal cancer. [PDF]

J Gastrointest Oncol
Archwamety A, Akewanlop C, Korphaisarn K.   +2 more
europepmc   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source

PANoptosis in the pathogenesis of myelodysplastic syndromes

Molecular Oncology, EarlyView.
PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla, Jyoti Lamichhane, Cameron Lewis, Peter Breslin, Jiwang Zhang   +4 more
wiley   +1 more source

Machine learning for survival outcome in head and neck squamous cell carcinoma: a multicenter validation study. [PDF]

Sci Rep
Alabi RO, Guntinas-Lichius O, Elmusrati M, Almangush A, Tiblom Ehrsson Y, Laurell G, Mäkitie AA.   +6 more
europepmc   +1 more source

Pole-Augmented Multidimensional Scaling Framework for Survival-Analysis Visualization

We introduce a multidimensional scaling framework that represents survival outcomes and covariates in a single two-dimensional map. Two reference points called poles represent the event direction and survival or non-event direction at a fixed follow-up ...
Takemi Mori
core  

Intrapatient tumour heterogeneity and clonal evolution in an autopsy study of metastatic salivary gland cancer

Molecular Oncology, EarlyView.
Tumour heterogeneity and clonal evolution of metastatic salivary gland cancer were evaluated in two patients with adenoid carcinoma and one patient with myoepithelial carcinoma. Radiology‐guided autopsy enabled multi‐region sampling (total samples n = 149), followed by whole‐genome sequencing and phylogenetic reconstruction (17 tumour samples, 4–7 per ...
Gerben Lassche, Niels J. van Ruitenbeek, Charlotte Adang, Luke O'Gorman, Pui Yuen Lee, Willemijn M. Klein, Adriana C. H. van Engen‐van Grunsven, Jack A. Schalken, Sander Bervoets, Gerald W. Verhaegh, Carla M. L. van Herpen   +10 more
wiley   +1 more source

Lysosome-derived biomarkers for predicting survival outcome in acute myeloid leukemia. [PDF]

Discov Oncol
Li G, Miao Y, Yuan F, Zhang W, Wu Y, Zhu L.   +5 more
europepmc   +1 more source

Congenital Chylothorax: Antenatal Intervention, Survival, and Outcome [PDF]

Pediatrics & Neonatology, 2016
openaire   +3 more sources

Somatostatin receptor 4 (SSTR4) is a tumor suppressor in cutaneous and head & neck squamous cell carcinomas

Molecular Oncology, EarlyView.
This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi, Tuan Khang Huynh, Adway Kadam, Zahra Kardan, Yue Yan, Amina Jamal Laham, Sampath Kumar Loganathan   +6 more
wiley   +1 more source

Survival outcome of airway stenting in patients with esophageal cancer with airway involvement. [PDF]

J Chin Med Assoc
Kuan CY, Liu C, Lee YY, Chien HC, Hung JJ, Huang CS, Hsu HS, Hsu PK.   +7 more
europepmc   +1 more source